The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 12, 2005, Pages 1088-1096

  Gao, Zhan ^a   Milnes, James T ^a   Choisy, Stéphanie C M ^a   Leach, Michael J ^b   Hancox, Jules C ^a   James, Andrew F ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

BW 619C89; Fast sodium current; Guinea pig cardiac myocytes; Inward rectifier; L type calcium current; Potassium current; Pro arrhythmia; Rapidly activating delayed rectifier; Slowly activating delayed rectifier; Ventricular myocytes

Indexed keywords

CALCIUM CHANNEL L TYPE; CHROMANOL 293B; DOFETILIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL; NEUROPROTECTIVE AGENT; SIPATRIGINE; SODIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; ION CHANNEL; PIPERAZINE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; PYRIMIDINE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; GUINEA PIG; HEART MUSCLE CELL; HEART REPOLARIZATION; HEART VENTRICLE WALL; IC 50; MALE; MEDICAL EXAMINATION; MODULATION; NEUROPROTECTION; NONHUMAN; POTASSIUM CURRENT; SODIUM CURRENT; TRIANGULATION; ANIMAL; CELL SEPARATION; ELECTROPHYSIOLOGY; HEART; HEART VENTRICLE; IN VITRO STUDY;

ACTION POTENTIALS; ANIMALS; CALCIUM CHANNEL BLOCKERS; CELL SEPARATION; ELECTROPHYSIOLOGY; GUINEA PIGS; HEART; HEART VENTRICLES; ION CHANNELS; MALE; MYOCYTES, CARDIAC; NEUROPROTECTIVE AGENTS; PIPERAZINES; POTASSIUM CHANNEL BLOCKERS; PYRIMIDINES; SODIUM CHANNEL BLOCKERS;

EID: 33644968894     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2005.04312.x     Document Type: Article

References (43)

1. Hainsworth AH Stefani A Calabresi P Smith TW Leach MJ. Sipatrigine (BW 6 19C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. CNS Drug Rev. 2000 6 : 111 34.
2. + channels TREK-1 and TRAAK. Brain Res. 2001 892 : 94 101.
3. Swan JH Leach MJ. Evaluation of the novel neuroprotective agent BW619C89 in the middle cerebral artery occlusion model of focal ischemia in the spontaneously hypertensive rat and normotensive Fischer 344 rat. Ann. N.Y. Acad. Sci. 1995 765 : 39 46.
4. Kawaguchi K Graham SH. Neuroprotective effects of the glutamate release inhibitor 619C89 in temporary middle cerebral artery occlusion. Brain Res. 1997 749 : 131 4.
5. Danielsson BR Lansdell K Patmore L Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res. 2005 63 : 17 25.
6. 2+ exchange current recorded from guinea-pig ventricular myocytes. Cell Calcium 2001 29 : 347 58.
7. James AF Arberry LA Hancox JC. Gender-related differences in ventricular myocyte repolarization in the guinea pig. Basic Res. Cardiol. 2004 99 : 183 92.
8. 1A- adrenoceptors in cardiac myocytes. Mol. Pharmacol. 2004 66 : 735 48.
9. Yuill KH Convery MK Dooley PC Doggrell SA Hancox JC. Effects of BDF 9 198 on action potentials and ionic currents from guinea-pig isolated ventricular myocytes. Br. J. Pharmacol. 2000 130 : 1753 66.
10. Miller A Nobbs M Hyde R Leach M, inventors. The Wellcome Foundation Ltd, assignee. Pharmacologically active CNS compounds. European Patent no. 0372934A2, application no. 89312723.3. December 1989.
11. + current: Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 1990 96 : 194 214.
12. Mitra R Morad M. Two types of calcium channels in guinea pig ventricular myocytes. Proc. Natl Acad. Sci. USA 1986 83 : 5340 4.
13. Ks in guinea-pig isolated ventricular myocytes. Exp. Physiol. 1996 81 : 605 21.
14. Kr, through a reduction in C-type inactivation in guinea-pig ventricular myocytes. J Physiol. 2000 522 : 391 402.
15. Sakmann B Trube G. Voltage-dependent inactivation of inward-rectifying single-channel currents in the guinea-pig heart cell membrane. J. Physiol. 1984 347 : 659 83.
16. Josephson IR Sanchez-Chapula J Brown AM. A comparison of calcium currents in rat and guinea pig single ventricular cells. Circ. Res. 1984 54 : 144 56.
17. Hondeghem LM Carlsson L Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential prolongation is antiarrhythmic. Circulation 2001 103 : 2004 13.
18. Tamargo J Caballero R Gomez R Valenzuela C Delpon E. Pharmacology of cardiac potassium channels. Cardiovasc. Res. 2004 62 : 9 33.
19. Ks heterogeneity on action potential duration and its rate dependence: A simulation study. Circulation 1999 99 : 2466 74.
20. Mitcheson JS Hancox JC. An investigation of the role played by the E-4031-sensitive (rapid delayed rectifier) potassium current in isolated rabbit atrioventricular nodal and ventricular myocytes. Pflügers Arch. 1999 438 : 843 50.
21. Linz KW Meyer R. Control of L-type calcium current during the action potential of guinea-pig ventricular myocytes. J. Physiol. 1998 513 : 425 42.
22. Calabresi P Stefani A Marfia GA et al. Electrophysiology of sipatrigine: A lamotrigine derivative exhibiting neuroprotective effects. Exp. Neurol. 2000 162 : 171 9.
23. 2+ channel currents. Eur. J. Pharmacol. 2003 467 : 77 80.
24. Liu G Yarov-Yarovoy V Nobbs M Clare JJ Scheuer T Catterall WA. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. Neuropharmacology 2003 44 : 413 22.
25. 2+ channels by the neuroprotective agent BW619C89. Neuropharmacology 1997 36 : 1795 8.
26. 2+ channels by the neuroprotective agent BW619C89 (sipatrigine). Neuropharmacology 2000 39 : 1247 53.
27. Stefani A Hainsworth A Spadoni F Bernardi G. On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89. Br. J. Pharmacol. 1998 125 : 1058 64.
28. + channels. Neuroscience 1996 73 : 951 62.
29. + channel alpha subunit. J. Biol. Chem. 2001 276 : 20 7.
30. Hockerman GH Peterson BZ Johnson BD Catterall WA. Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol. 1997 37 : 361 96.
31. Mitcheson JS Perry MD. Molecular determinants of high-affinity drug binding to HERG channels. Curr. Opin. Drug Discov. Dev. 2003 6 : 667 74.
32. Hainsworth AH Spadoni F Lavaroni F Bernardi G Stefani A. Effects of extracellular pH on the interaction of sipatrigine and lamotrigine with high-voltage-activated (HVA) calcium channels in dissociated neurones of rat cortex. Neuropharmacology 2001 40 : 784 91.
33. Haverkamp W Breithardt G Camm AJ et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Cardiovasc. Res. 2000 47 : 219 33.
34. Redfern WS Carlsson L Davis AS et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003 58 : 32 45.
35. Hondeghem LM Dujardin K De Clerck F. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc. Res. 2001 50 : 345 53.
36. Milberg P Ramtin S Monnig G et al. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. J. Cardiovasc. Pharmacol. 2004 44 : 278 86.
37. + current in guinea-pig sino-atrial node pacemaker cells. J. Physiol. 2002 540 : 815 30.
38. Mercer AJ Lamb RJ Hussein Z Hobbiger S Posner J. The tolerability, pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers. Ann. N.Y. Acad. Sci. 1995 765 : 324 6.
39. Hussein Z Fraser IJ Lees KR et al. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions. Br. J. Clin. Pharmacol. 1996 41 : 505 11.
40. Muir KW Hamilton SJ Lunnon MW Hobbiger SF Lees KR. Safety and tolerability of 619C89 after acute stroke. Cerebrovasc. Dis. 1998 8 : 31 7.
41. Muir KW Holzapfel L Lees KR. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Cerebrovasc. Dis. 2000 10 : 431 6.
42. Bril A Forest M-C Cheval B Faivre J-F. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration. Comparison between BRL-32872 and azimilide. Cardiovasc. Res. 1998 37 : 130 40.
43. Kodama I Kamiya K Toyama J. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol. 1999 84 : R20 8.